- Home
- AIRI vs ONCO Comparison
AIRI vs ONCO Comparison
Compare AIRI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- ONCO
- Stock Information
- Founded
- AIRI 1979
- ONCO 2018
- Country
- AIRI United States
- ONCO United States
- Employees
- AIRI N/A
- ONCO N/A
- Industry
- AIRI Military/Government/Technical
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- ONCO Health Care
- Exchange
- AIRI Nasdaq
- ONCO Nasdaq
- Market Cap
- AIRI 20.2M
- ONCO 24.1M
- IPO Year
- AIRI N/A
- ONCO 2022
- Fundamental
- Price
- AIRI $4.60
- ONCO $1.27
- Analyst Decision
- AIRI
- ONCO
- Analyst Count
- AIRI 0
- ONCO 0
- Target Price
- AIRI N/A
- ONCO N/A
- AVG Volume (30 Days)
- AIRI 67.0K
- ONCO 71.6K
- Earning Date
- AIRI 11-14-2024
- ONCO 11-26-2024
- Dividend Yield
- AIRI N/A
- ONCO N/A
- EPS Growth
- AIRI N/A
- ONCO N/A
- EPS
- AIRI N/A
- ONCO N/A
- Revenue
- AIRI $53,657,000.00
- ONCO $1,463,746.00
- Revenue This Year
- AIRI $9.26
- ONCO N/A
- Revenue Next Year
- AIRI $8.73
- ONCO N/A
- P/E Ratio
- AIRI N/A
- ONCO N/A
- Revenue Growth
- AIRI 3.31
- ONCO N/A
- 52 Week Low
- AIRI $2.89
- ONCO $1.27
- 52 Week High
- AIRI $9.44
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- AIRI 32.15
- ONCO 20.68
- Support Level
- AIRI $5.63
- ONCO $1.70
- Resistance Level
- AIRI $6.18
- ONCO $2.53
- Average True Range (ATR)
- AIRI 0.36
- ONCO 0.28
- MACD
- AIRI -0.13
- ONCO -0.14
- Stochastic Oscillator
- AIRI 6.15
- ONCO 0.00
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.